|
Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN). |
| |
|
Consulting or Advisory Role - Pfizer |
Research Funding - Baxter; Pfizer |
Travel, Accommodations, Expenses - Takeda |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer |
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer |
Research Funding - Pfizer |
Travel, Accommodations, Expenses - Novartis; Pfizer |
| |
|
Honoraria - novartis; pfizer |
Travel, Accommodations, Expenses - novartis; pfizer |
| |
|
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi |
Research Funding - Novartis (Inst); Pfizer (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |